BioWorld

July 23, 2003

View Archived Issues

Roche Licenses Rights To IL-15 Preclinical Program From Cardion

Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today) Read More

House Passes BioShield Bill That Excludes Two Industry Incentives

Read More

Vancomycin Can't Buck All Bugs; Hospitals Call All Hands To Curb Patient Infection, Test New Drug

Read More

Symyx Signs ExxonMobil Deal: $200M For Fuel-Products Work

Read More

Onyx Raises $71M In Public Offering Of 5 Million Shares

Read More

Diversa Acquiring GSK Antifungal Compounds For $8.6M In Equity

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More